Share C5aR is a complement factor that has been found localized in drusen and on the edges of geographic atrophy.  Preclinical studies have suggested that blocking C5aR could be useful in stopping wet macular degeneration. One of the hopes we have in research is that we can find something that will stop dry AMD from advancing to wet AMD. For dry AMD, this drug is being studied to see if it will reduce drusen and the size of geographic atrophy. This is a randomized, double-arm, double-masked study designed to evaluate the safety and efficacy of eculizumab for the treatment of patients with dry AMD.  The treatment is an IV infusion from a company called Alexion.  It is taking place in one location in Florida.  For more information, visit ClinicalTrials.gov.